A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

✍ Scribed by Mathews Adera; Allison Gladden; Pol Boudes

• Book ID: 116989110
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 60 KB
• Volume: 102
• Category: Article
• ISSN: 1096-7192
• DOI: 10.1016/j.ymgme.2010.11.012